Shareholders Would Not Be Objecting To Kilitch Drugs Limiteds CEO Compensation And Heres Why - Simply Wall St
| KILITCH Stock | 310.05 3.95 1.29% |
Under 50% of Kilitch Drugs' traders are presently thinking to get in. The analysis of overall sentiment of trading Kilitch Drugs Limited stock suggests that some investors are interested at this time. Kilitch Drugs' investing sentiment shows overall attitude of investors towards Kilitch Drugs Limited.
Kilitch |
Shareholders Would Not Be Objecting To Kilitch Drugs Limiteds CEO Compensation And Heres Why Simply Wall St
Read at news.google.com
 |
Kilitch Drugs Fundamental Analysis
We analyze Kilitch Drugs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kilitch Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kilitch Drugs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Kilitch Drugs is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Kilitch Drugs Limited Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kilitch Drugs stock to make a market-neutral strategy. Peer analysis of Kilitch Drugs could also be used in its relative valuation, which is a method of valuing Kilitch Drugs by comparing valuation metrics with similar companies.
Peers
Kilitch Drugs Related Equities
| APOLLOHOSP | Apollo Hospitals | 2.86 | ||||
| TATACOMM | Tata Communications | 1.65 | ||||
| BLUEJET | Blue Jet | 1.19 | ||||
| MEDPLUS | Medplus Health | 0.84 | ||||
| SAKAR | Sakar Healthcare | 0.49 | ||||
| PNC | Pritish Nandy | 0.03 | ||||
| ENTERO | Entero Healthcare | 0.14 |
Complementary Tools for Kilitch Stock analysis
When running Kilitch Drugs' price analysis, check to measure Kilitch Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kilitch Drugs is operating at the current time. Most of Kilitch Drugs' value examination focuses on studying past and present price action to predict the probability of Kilitch Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kilitch Drugs' price. Additionally, you may evaluate how the addition of Kilitch Drugs to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |